Related Experiment Video
Updated: Jul 10, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Thalidomide analogues as anticancer drugs.
Jeanny B Aragon-Ching1, Haiqing Li, Erin R Gardner
1Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Recent Patents on Anti-Cancer Drug Discovery
|November 3, 2007
Summary
New thalidomide analogues, known as Immunomodulatory drugs (IMiDs), show promise for treating various cancers. These compounds offer potent anti-tumor effects with fewer side effects than traditional treatments.
Area of Science:
- Oncology
- Pharmacology
- Medicinal Chemistry
Background:
- Thalidomide's success in neoplasms spurred research for improved analogues.
- Immunomodulatory drugs (IMiDs) emerged, retaining therapeutic effects with reduced adverse reactions.
- Lenalidomide (CC-5013) and Actimid (CC-4047) are key IMiDs with recent FDA approvals and ongoing clinical trials.
Purpose of the Study:
- To review preclinical and clinical data of thalidomide analogues.
- To discuss novel analogues like ENMD-0995, CPS11, and CPS49.
- To explore patents and findings for these emerging anti-cancer agents.
Main Methods:
- Review of existing preclinical and clinical data.
- Synthesis and screening of novel thalidomide analogues.
- Analysis of patent literature.
Main Results:
- Thalidomide analogues demonstrate potent anti-tumor and antiangiogenic effects.
- IMiDs show efficacy in hematologic malignancies and are under investigation for solid tumors.
- Novel analogues exhibit promising activity in early-stage research.
Conclusions:
- Thalidomide analogues represent a significant advancement in cancer therapy.
- Continued development of IMiDs holds potential for improved cancer treatment outcomes.
- Further research into novel analogues is warranted for broader clinical application.
Related Concept Videos
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...